Skip to main content

Advertisement

SpringerLink
Log in

Effects of RAAS Inhibitors in Patients with Kidney Disease

  • Hypertension and the Kidney (RM Carey, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Proteinuria and decline of renal function are associated with progression of kidney disease. The Renin Angiotensin Aldosterone System (RAAS) plays an important role in blood pressure regulation, fluid volume, and sodium balance. Overactivity of RAAS contributes to the pathogenesis of a variety of clinical conditions including progress of chronic kidney disease (CKD). This review summarizes the use of RAAS inhibitors as dual therapy or monotherapy in different stages of kidney disease. Experimental and clinical studies have demonstrated RAAS inhibitors prevent proteinuria, kidney fibrosis and slow decline of renal function and thus play a protective role in both early and end stages of kidney disease. While combination use of RAAS inhibitors showed higher efficiency compared with monotherapy, it is also associated with higher incidence of adverse events. Besides ACEI/ARBs, more mechanism research of mineralocorticoid receptor antagonists in kidney disease should be performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail. 2009;31(9):779–84.

    Article  CAS  PubMed  Google Scholar 

  2. Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Shirai Y, et al. Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem. 2012;19(12):1889–98.

    Article  CAS  PubMed  Google Scholar 

  3. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73(12):1419–25.

    Article  CAS  PubMed  Google Scholar 

  4. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52(1):130–6.

    Article  CAS  PubMed  Google Scholar 

  5. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50(11):2398–404.

    Article  CAS  PubMed  Google Scholar 

  6. •• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–92. The "aldosterone escape phenomenon” which is the basis of a combination of RAAS inhibitors and residual renal function, protected with RAAS inhibitors, plays an important role in preservation of survival and quality of life of ESRD patients.

    Article  CAS  PubMed  Google Scholar 

  7. •• Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2(1):47–54 (see comment above).

    Article  CAS  PubMed  Google Scholar 

  8. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond). 2001;100(6):591–9.

    Article  CAS  Google Scholar 

  9. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant. 2001;16(7):1343–9.

    Article  CAS  PubMed  Google Scholar 

  10. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345(12):925–6.

    Article  CAS  PubMed  Google Scholar 

  12. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56(4):714–9.

    Article  CAS  PubMed  Google Scholar 

  13. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940–51.

    Article  CAS  PubMed  Google Scholar 

  14. Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol. 2015;19(6):1098–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int Suppl. 1997;63:S229–31.

    CAS  PubMed  Google Scholar 

  16. Wang H, Fu W, Jin Z, Wang Y, Yao W, Yin P, et al. Advanced IgA nephropathy with impaired renal function benefits from losartan treatment in rats. Ren Fail. 2013;35(6):812–8.

    Article  CAS  PubMed  Google Scholar 

  17. Banki NF, Ver A, Wagner LJ, Vannay A, Degrell P, Prokai A, et al. Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats. PLoS One. 2012;7(6):e39938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2116–23.

    Article  CAS  PubMed  Google Scholar 

  19. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16(11):3306–14.

    Article  CAS  PubMed  Google Scholar 

  20. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int. 2003;63(1):172–8.

    Article  CAS  PubMed  Google Scholar 

  21. Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, et al. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. Am J Med Sci. 2016;351(3):309–16.

    Article  PubMed  Google Scholar 

  22. •• Brener ZZ, Kotanko P, Thijssen S, Winchester JF, Bergman M. Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians. Am J Med Sci. 2010;339(5):453–6. The "aldosterone escape phenomenon” which is the base of combination of RAAS inhibitors and residual renal fucntion, protected with RAAS inhibitors, plays an important role in preservation of survival and quality of life of ESRD patients.

    Article  PubMed  Google Scholar 

  23. •• Bargman JM, Thorpe KE, Churchill DN, Group CPDS. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–62 (see comment above).

    CAS  PubMed  Google Scholar 

  24. •• Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307–20 (see comment above).

    CAS  PubMed  Google Scholar 

  25. • Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11(3):556–64. This demonstrated that ACEI/ARB has a beneficial effect on RRF of ESRD patients and possible mechanisms.

    CAS  PubMed  Google Scholar 

  26. • Reyes-Marín FA, Calzada C, Ballesteros A, Amato D. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. a randomized controlled study. Rev Invest Clin. 2012;64(4):315–21 (see comment above).

    PubMed  Google Scholar 

  27. Xydakis D, Papadogiannakis A, Sfakianaki M, Kostakis K, Stylianou K, Petrakis I, et al. Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol. 2013;2013:184527.

    Article  PubMed  Google Scholar 

  28. • Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57(5):1803–17 (see comment above).

    Article  CAS  PubMed  Google Scholar 

  29. • Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005;25(1):38–47 (See comment above).

    CAS  PubMed  Google Scholar 

  30. • Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial. 2003;19:180–5 (See comment above).

    CAS  PubMed  Google Scholar 

  31. Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol. 2003;14(12):3061–71.

    Article  CAS  PubMed  Google Scholar 

  32. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant. 2001;16(11):2207–13.

    Article  CAS  PubMed  Google Scholar 

  33. • Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int. 2005;25(5):483–91 (See comment above).

    CAS  PubMed  Google Scholar 

  34. Luo W, Meng Y, Ji HL, Pan CQ, Huang S, Yu CH, et al. Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One. 2012;7(3):e34230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mummidi S, Das NA, Carpenter AJ, Kandikattu H, Krenz M, Siebenlist U, et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol. 2016;98:95–102.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest. 2014;94(8):839–50.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China

    Fan Zhang, Hong Liu, Di Liu, Yexin Liu, Huiqiong Li, Xia Tan, Fuyou Liu, Youming Peng & Hongqing Zhang

Authors
  1. Fan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Di Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yexin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huiqiong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xia Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fuyou Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Youming Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hongqing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Liu.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and the Kidney

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, F., Liu, H., Liu, D. et al. Effects of RAAS Inhibitors in Patients with Kidney Disease. Curr Hypertens Rep 19, 72 (2017). https://doi.org/10.1007/s11906-017-0771-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0771-9

Keywords

Search

Navigation